Zynerba Pharmaceuticals, Inc. (ZYNE:NASDAQ) Investor Relations Material

Overview

Devon, PA-based clinical stage specialty pharmaceutical company, Zynerba Pharmaceuticals, Inc., is making strides in the development of pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. One promising drug in the works is Zygel, a cannabidiol drug created as a permeation-enhanced gel for transdermal delivery. Zynerba Pharmaceuticals, Inc. was formerly known as AllTranz, Inc. before a name change in August 2014. The company was founded in 2007 and is currently run out of Devon, PA.

Annual Reports

Frequently Asked Questions

What is Zynerba Pharmaceuticals, Inc.'s ticker?

Zynerba Pharmaceuticals, Inc.'s ticker is ZYNE

What exchange is Zynerba Pharmaceuticals, Inc. traded on?

The company's shares trade on the NASDAQ stock exchange

Where are Zynerba Pharmaceuticals, Inc.'s headquarters?

They are based in Devon, Pennsylvania

How many employees does Zynerba Pharmaceuticals, Inc. have?

There are 11-50 employees working at Zynerba Pharmaceuticals, Inc.

What is Zynerba Pharmaceuticals, Inc.'s website?

It is https://zynerba.com/

What type of sector is Zynerba Pharmaceuticals, Inc.?

Zynerba Pharmaceuticals, Inc. is in the Healthcare sector

What type of industry is Zynerba Pharmaceuticals, Inc.?

Zynerba Pharmaceuticals, Inc. is in the Biotechnology industry

Who are Zynerba Pharmaceuticals, Inc.'s peers and competitors?

The following five companies are Zynerba Pharmaceuticals, Inc.'s industry peers:

- Osmotica Pharmaceuticals plc

- OKYO Pharma Limited

- Kaleido Biosciences, Inc.

- Karuna Therapeutics

- BioXcel Therapeutics